Radius Health (NASDAQ: RDUS) is one of 296 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its competitors? We will compare Radius Health to related businesses based on the strength of its profitability, institutional ownership, risk, earnings, analyst recommendations, valuation and dividends.
This is a breakdown of current ratings and target prices for Radius Health and its competitors, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Radius Health Competitors||765||3044||11230||227||2.72|
Radius Health currently has a consensus target price of $52.17, indicating a potential upside of 60.07%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 35.85%. Given Radius Health’s higher possible upside, equities research analysts clearly believe Radius Health is more favorable than its competitors.
Valuation and Earnings
This table compares Radius Health and its competitors top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Radius Health||$980,000.00||-$225.19 million||-6.28|
|Radius Health Competitors||$260.16 million||$66.28 million||-6.36|
Radius Health’s competitors have higher revenue and earnings than Radius Health. Radius Health is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
This table compares Radius Health and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Radius Health Competitors||-5,489.25%||-451.68%||-42.65%|
Risk & Volatility
Radius Health has a beta of 1.33, indicating that its stock price is 33% more volatile than the S&P 500. Comparatively, Radius Health’s competitors have a beta of 6.62, indicating that their average stock price is 562% more volatile than the S&P 500.
Institutional & Insider Ownership
50.4% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 15.0% of Radius Health shares are owned by insiders. Comparatively, 16.4% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Radius Health competitors beat Radius Health on 9 of the 12 factors compared.
About Radius Health
Radius Health, Inc. is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Company’s clinical pipeline also includes an investigational abaloparatide transdermal patch for potential use in osteoporosis and the investigational drug elacestrant (RAD1901) for potential use in hormone-driven and/or hormone-resistant breast cancer, and vasomotor symptoms in postmenopausal women. Its RAD140 is a non-steroidal, selective androgen receptor modulator (SARM). RAD140 is under development for potential use in hormone receptor positive breast cancer.
What are top analysts saying about Radius Health Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Radius Health Inc. and related companies.